Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 201 to 250 of 2053 results for work

  1. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

    In development Reference number: GID-TA11025 Expected publication date: TBC

  2. Involving you in the development of our guidance

    Involving you in the development of NICE guidance.

  3. Involving you in the development of our guidance

    Involving you in the development of NICE guidance.

  4. Social care

    ng-nice-guidance","name":"Implementing NICE guidance"}}]} Social care We work with the adult and children's care sectors to develop...

  5. Social care for older people with multiple long-term conditions (QS132)

    This quality standard covers the planning and delivery of social care and support for older people (aged 65 and over) with multiple long-term conditions. It includes people living in their own homes, in specialist settings or in care homes, both those who receive support with funding for their social care and those who do not. It describes high-quality care in priority areas for improvement.

  6. Mental health of adults in contact with the criminal justice system (NG66)

    This guideline covers assessing, diagnosing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system. It aims to improve mental health and wellbeing in this population by establishing principles for assessment and management, and promoting more coordinated care planning and service organisation across the criminal justice system.

  7. Digital at NICE

    Jobs in digital at NICE. Come and join us!

  8. NICE International

    Providing an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care

  9. Mental wellbeing at work (PH22)

    This guideline has been updated and replaced by NICE guideline NG212.

  10. Pancreatic cancer (QS177)

    This quality standard covers diagnosis of pancreatic cancer and management of pancreatic ductal adenocarcinoma in adults aged over 18. This quality standard describes high-quality care in priority areas for improvement. It does not cover national initiatives, such as cancer screening or audit.

  11. Air pollution: outdoor air quality and health (NG70)

    This guideline covers road-traffic-related air pollution and its links to ill health. It aims to improve air quality and so prevent a range of health conditions and deaths.

  12. Flu vaccination: increasing uptake (NG103)

    This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.

  13. Child abuse and neglect guidance

    Find individual child abuse and neglect recommendations quickly and links to full guideline.

  14. Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) (TA965)

    NICE is unable to make a recommendation on human alpa1-proteinase inhibitor (Respreeza) for treating emphysema in adults. CSL Behring UK has confirmed that it does not intend to launch the product in England and Wales. The reasons for this decision are primarily related to the company’s inability to offer the product at a price to meet the current threshold of cost effectiveness.

    Sections for TA965

  15. Getting involved as someone with lived experience

    We want you to help NICE to develop our guidance for NHS and care services.

  16. Getting involved as someone with lived experience

    We want you to help NICE to develop our guidance for NHS and care services.

  17. Health Technology Assessment Innovation Laboratory (HTA Lab)

    NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

  18. Hepatitis B (QS65)

    This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.

  19. International collaboration

    International collaboration with NICE

  20. IHI and H2020 Grant funded projects

    IMI and H2020 Grant funded projects with NICE

  21. Join our people and communities network

    Join NICE's people and communities network

  22. Join our people and communities network

    Join NICE's people and communities network

  23. Costing tool:- Which elements of health, social care or other support services work best at a local level and provide the best 'value for money' to address the needs of young people and adults with coexisting severe mental illness and substance misuse?

    Costing tool:- Which elements of health, social care or other support services work best at a local level and provide the best 'value...

  24. Osteoporosis

    In development Reference number: GID-QS10188 Expected publication date: TBC

  25. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

    In development Reference number: GID-TA10726 Expected publication date:  13 May 2026

  26. Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

    Awaiting development Reference number: GID-QS10106 Expected publication date: TBC

  27. Gambling

    Awaiting development Reference number: GID-QS10099 Expected publication date: TBC

  28. Secondary care management of malignant hypertension

    Awaiting development Reference number: GID-QS10107 Expected publication date: TBC

  29. How voluntary and community sector organisations can help us develop guidance

    How voluntary and community sector (VCS) organisations can help NICE develop guidance

  30. How voluntary and community sector organisations can help us develop guidance

    How voluntary and community sector (VCS) organisations can help NICE develop guidance

  31. About NICE guidelines

    NICE guidelines are evidence-based recommendations for health and care in England and Wales.

  32. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date: TBC

  33. What NICE does

    We're at the forefront of bringing better care to people. We help practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

  34. Acne

    Awaiting development Reference number: GID-QS10036 Expected publication date: TBC

  35. Adrenal dysfunction

    Awaiting development Reference number: GID-QS10038 Expected publication date: TBC

  36. Pancreatitis (including acute pancreatitis)

    Awaiting development Reference number: GID-QS10085 Expected publication date: TBC

  37. Diverticular disease

    Awaiting development Reference number: GID-QS10086 Expected publication date: TBC

  38. Thyroid disease

    Awaiting development Reference number: GID-QS10088 Expected publication date: TBC

  39. Tinnitus

    Awaiting development Reference number: GID-QS10091 Expected publication date: TBC

  40. Pain management (young people and adults)

    Awaiting development Reference number: GID-QS10093 Expected publication date: TBC

  41. Shared decision-making: practical guidance for health and social care professionals

    Awaiting development Reference number: GID-QS10097 Expected publication date: TBC

  42. Gout

    Awaiting development Reference number: GID-QS10100 Expected publication date: TBC

  43. Heart valve disease in adults

    Awaiting development Reference number: GID-QS10101 Expected publication date: TBC

  44. Managing symptoms with an uncertain cause

    Awaiting development Reference number: GID-QS10103 Expected publication date: TBC

  45. Vulnerable populations: strategies for tackling inequalities

    Awaiting development Reference number: GID-QS10124 Expected publication date: TBC

  46. Pelvic floor dysfunction

    Awaiting development Reference number: GID-QS10129 Expected publication date: TBC

  47. Pernicious anaemia

    Awaiting development Reference number: GID-QS10130 Expected publication date: TBC

  48. Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care

    Awaiting development Reference number: GID-QS10144 Expected publication date: TBC

  49. Advocacy services for adults with health and social care needs

    Awaiting development Reference number: GID-QS10145 Expected publication date: TBC

  50. Children and young people with disabilities and severe complex needs: integrated health and social care support

    Awaiting development Reference number: GID-QS10146 Expected publication date: TBC